Anti-CD20 chimeric monoclonal antibody that depletes B cells via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
YES
DIRECT
Binding to CD20 on B cells triggers Fc-mediated ADCC by effector cells, complement-dependent cytotoxicity, and CD20 crosslinking–induced apoptosis.
Individualized neoantigen mRNA cancer vaccine that encodes patient-specific tumor neoantigens; after intramuscular injection, APCs (especially dendritic cells) translate the mRNA and present peptides on MHC I/II to prime and expand tumor-specific CD8+ and CD4+ T cells.
Individualized mRNA vaccine encoding patient-specific tumor neoantigens. After intramuscular injection, antigen-presenting cells (notably dendritic cells) take up the mRNA, translate it into neoantigen proteins, and present peptides on MHC I and II to prime and expand tumor-specific CD8+ cytotoxic and CD4+ helper T cells, driving anti-tumor immunity.
YES
INDIRECT
The vaccine primes neoantigen-specific CD8+ T cells, which recognize the neoantigen peptide–MHC I complexes on tumor cells and kill them via perforin/granzyme cytolysis and Fas–FasL–mediated apoptosis.
An intravenous, glycoengineered type II anti-CD20 humanized IgG1 monoclonal antibody that induces B-cell death and immune effector killing (ADCC/ADCP; some CDC).
Humanized, glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and triggers direct B‑cell death and Fc-mediated effector killing (enhanced ADCC/ADCP with limited CDC) via increased affinity of its afucosylated Fc for FcgammaRIIIa.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages FcγRIIIa (CD16a) on NK cells/macrophages to drive ADCC/ADCP and direct type II B‑cell death. CD16a+ effector cells are not killed.
Individualized neoantigen mRNA cancer vaccine that encodes patient-specific tumor neoantigens; after intramuscular injection, APCs (especially dendritic cells) translate the mRNA and present peptides on MHC I/II to prime and expand tumor-specific CD8+ and CD4+ T cells.
Individualized mRNA vaccine encoding patient-specific tumor neoantigens. After intramuscular injection, antigen-presenting cells (notably dendritic cells) take up the mRNA, translate it into neoantigen proteins, and present peptides on MHC I and II to prime and expand tumor-specific CD8+ cytotoxic and CD4+ helper T cells, driving anti-tumor immunity.
NO
INDIRECT
The vaccine primes neoantigen-specific T cells via APC presentation; tumor killing occurs when CD8+ CTLs recognize neoantigen peptides on MHC I and induce perforin/granzyme-mediated apoptosis. Cells presenting MHC II–restricted neoantigen peptides (typically APCs) are not directly killed by the drug.
Anti-CD30 antibody–drug conjugate (ADC) linked to MMAE; binds CD30 on malignant T cells, internalizes, and releases MMAE to disrupt microtubules, causing G2/M arrest and apoptosis (possible bystander effect).
Anti-CD30 monoclonal antibody linked via a cleavable valine-citrulline linker to MMAE; upon binding CD30 and internalization, MMAE is released to inhibit tubulin polymerization, leading to G2/M arrest and apoptosis (with potential bystander effect).
YES
DIRECT
Anti-CD30 ADC binds CD30, is internalized, linker is cleaved to release MMAE, which inhibits tubulin polymerization causing G2/M arrest and apoptosis (with possible bystander effect).